INTRODUCTION
Philadelphia Chromosome "negative" myeloproliferative neoplasms (MPN) is a diverse group of hematological malignancies. MPNs are characterized by stem cell-derived clonal myeloproliferation primarily characterized by erythrocytosis and thrombocytosis with predisposition to thrombosis, bleeding, and the possibility of leukemic transformation. Polycythemia vera (PV) and essential thrombocythemia (ET) patients are characterized by an increased incidence of arterial and venous thromboses and by microcirculatory disturbances which often manifest in the diagnosis or in the preclinical phase of the disease. (Michiels, Abels et al. 1985) To prevent a significant number of early vascular events is still one of the most important challenges in the disease management, because thrombosis could be a major cause of morbidity and mortality in patients in many cases. (Tefferi 2012 ) Thus an effective antithrombotic strategy has to be started as soon as the disease is diagnosed. According to the international protocols, this strategy mostly includes treatment in different combination of low-dose aspirin, clopidogrel bisulfate, hydroxyurea, and interferon therapy. Phlebotomy also could be used accordingly as a risk adapted decision. (Vladareanu 2010)
SUMMARY OF THE RELEVANT LITERATURE
Several epidemiological studies performed in the field of the nutrition and physical activity of the general population are predictors of age-specific mortality and cardiovascular events. The connection between cardiovascular risk factors and thrombosis is not doubted any more, and the identification and appropriate management of cardiovascular risk factors, the promotion of a healthy lifestyle in the general population have become important and popular. According to the World Heart Federation's opinion: (Bas, But what about patients with MPNs? Does diet have as important a role as in the general population? On the contrary, the importance of a healthy lifestyle is frequently misjudged in MPN patients due to the tendency to consider thrombosis as it has been "caused" by the disease rather than by the interplay of various factors. ECLAP is a randomized trial (European Collaboration on Low-dose Aspirin in Polycythemia Vera ), which has many observations to support the idea that besides the basic medical antithrombotic strategy, we have to focus more on the modifiable risk factors in MPN patients as well. According to the publication of Finazzi G. in 2004, the cumulative incidence rate of cardiovascular events (i.e., cardiovascular death and non-fatal thrombotic events) was 5.5 events/100 persons per year. The main cause of death was thrombosis. Their results showed that the two most important predictors of cardiovascular events were age (higher than 65 years) and positive history of thrombosis. Nevertheless, they have found smoking, hypertension and congestive heart failure to be further significant risk factors for thrombosis. (Finazzi 2004) In the same trial in 2007, Landolfi et al. also described smoking as a habit that had an important effect on vascular risk associated with a significantly higher risk of arterial thrombotic events, and not just in the general population but among PV patients as well. A similar finding had been reported also in ET subjects by Besses Additionally, the ECLAP observational study has shown that diabetes was a possible predictor of survival and cardiovascular mortality in MPN patients. According to the above mentioned studies, it is supposed that arterial hypertension, hypercholesterolemia, obesity and metabolic syndrome, the well-known major risk factors for the development of cardiovascular diseases in the general population, could have an important role as the predictors of thrombosis in MPN patients despite the limited results. But surprisingly, we could find publications which rather contradicted the above mentioned notions. A few clinicians like Besses have found that ET patients demonstrated the independent contribution of hypercholesterolemia in predicting thrombosis. (Besses, Cervantes et al. 1999) According to the relevant literature, the efficacy of statins in MPNs has yet to be tested in prospective studies, but their possible use in MPNs deserves clinical and scientific attention. In the view of nutrition, epidemiological studies and clinical trials indicate the importance of nutrition. In a prospective study, over 12 years, 14,962 middle-aged adults participating in the Atherosclerosis Risk in Communities Study were followed up for incident VTE. According to their conclusion, it could be supposed that diet including more plant food and fish, and less red and processed meat could be associated with a lower incidence of venous thromboembolism. According to the relevant literature in myeloproliferative neoplasms, the suspected factors could play an important role in the development of thrombosis in MPN patients, as a conclusion showed in Table 2 . 
CONCLUSIONS
The American Dietetic Association introduced a new aim in 2010, the goal of which is the integration of "Medical Nutrition Therapy (MNT) and Pharmacotherapy" and introduced many guidelines as in diabetes mellitus, summarizing the evidence for the effectiveness of MNT in preventing and treating diabetes, and providing physicians with information on how to refer patients to MNT. The initiation and ongoing use of medical therapy is essential in myeloproliferative patients to prevent the development of disease complications and to manage the disease appropriately. As the life expectancy of patients in adequate condition is very promising, the survival years can reach up to several decades. Although the most frequent cause of death is patients is thrombosis, it is an interesting question whether conscious life style of these patients can lead to the achievement of a more beneficial therapy and whether thrombotic events may be prevented to a certain extent (parallel to medical therapy), thus achieving a longer life span. Conscious, healthy nutrition has an unequivocal role in preserving vascular intactness, and therefore, further investigation is needed in this topic. It is also vital to encourage patients to follow a healthy lifestyle. Nevertheless, its possible use in MPNs deserves clinical and scientific attention. Therefore, diet as one of the environmental factors has an impact on the development of thrombosis and hemostasis, and macronutrients, micronutrients, and other bioactive food components may alter the predisposition to thrombosis. However, in many cases such as the management of diabetes, the evidence is strong that medical nutrition therapy provided by registered dietitians is an effective and essential therapy, but in MPN neoplasms no strong evidence has been established yet. Though according to the known details, this notion should not be neglected, especially in the view of controlling risk factors.
